Physician

Oncology

Dr. Anthony J. Murgo, MD

Anthony Murgo is an expert in the field of Oncology. He graduated from State University of New York Downstate Medical Center College of Medicine. Anthony Murgo is also published. He has 36 publications published. The lastest publication: "A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.'

Publications

A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Recept...
Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.
FDA Approval Summary: Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: u.s. Food and...
Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors.
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1? in advanced solid tumors.
Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells.
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy.
The observation that changes in DNA methylation potentially play a role in neoplastic transformation has existed for nearly 30 years. Foreword.
DNA methylation: its role in cancer development and therapy.
Designing phase 0 cancer clinical trials.
Phase 0 clinical trials: conceptions and misconceptions.
Improving the quality of abstract reporting for phase I cancer trials.
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leuke...
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
Development of novel anticancer agents in older patients: pharmacokinetic, pharmacodynamic, and other considerations.
Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Clinical trials referral resource. Current clinical trials of imatinib mesylate.
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer.

Schools

Suny Downstate Medical Center
Maimonides Med Center
Sloan Kettering Cancer Center

Doctors Specialties

Medical Oncology
Oncology

Accepted Insurances

Education

Memorial Sloan-Kettering Cancer Center
Maimonides Medical Center
State University of New York Downstate Medical Center College of Medicine

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Frank J. Hsu, MD This Doctor is OpenDoctor Recommended.
	Dr. Grace E. Sagayadan, MD This Doctor is OpenDoctor Recommended.
	Dr. Leon C. Hwang, MD This Doctor is OpenDoctor Recommended.
	Dr. Mahrukh M. Hussain, MD This Doctor is OpenDoctor Recommended.